Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hologic

This article was originally published in The Gray Sheet

Executive Summary

Firm names John Cumming president/CEO Aug. 1. Cumming joined the firm in August 2000 as senior-VP and president of Hologic's Lorad subsidiary. Jay Stein, who served as interim CEO following the death of David Ellenbogen June 21, retains the post of chief technology officer and chairman (1"The Gray Sheet" July 2, 2001, In Brief). Steve Nakashige, president/chief operating officer, has resigned "to pursue other business opportunities," Hologic says

You may also be interested in...



Hologic's David Ellenbogen

Jay Stein, Hologic executive VP and chief technology officer, is appointed chairman and interim CEO following the death of Chairman, CEO and co-founder Ellenbogen June 21 due to heart failure

Chinese Firms Up Their Game In Novel Flu Antiviral Development

Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.

Quotable: Words Of Wisdom From Our Recent APAC Coverage

Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT015251

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel